目的：了解心房颤动患者抗凝治疗现状，为心房颤动规范化抗凝治疗提供参考。方法：选取皖南医学院弋矶山医院2013年1月~2014年12月非瓣膜性心房颤动患者200例，采用CHA2DS2-VASc和HAS-BLED评分系统对纳入人群进行血栓危险分层和出血风险评估，并依据《2010年欧洲心脏病学会（ESC）心房颤动治疗指南》评价其规范化抗凝情况。结果：CHA2DS2-VASc和HAS-BLED评分分别为（2.73±2.10）分和（1.57±1.13）分。183例（91.5%）患者接受抗血栓治疗，使用华法林抗凝治疗的有74例（37%），而血栓高危组125例患者中，接受华法林抗凝治疗50例（40%）。华法林抗凝治疗时间（5.78±4.73） d，累积给药剂量为（19.46±18.19） mg，55例（74.32%）患者出院前监测国际标准化比值（INR），INR达标率为30.9%。结论：心房颤动以华法林抗凝治疗现状不容乐观，应采取有效的干预措施，提高心房颤动患者抗凝治疗规范化程度。%Objective: To investigate the current state of anticoagulant therapy with warfarin in the pa-tients with atrial fibrillation in order to provide references on the standardized anticoagulant therapy. Meth-ods: A total of 200 patients diagnosed non-valvular atrial fibrillation were inspected from January 2013 to December 2014 in the Yijishan Hospital of Wannan Medical College. CHA2DS2-VASc and HAS-BLED scheme methods were used to assess the risk of thrombosis and hemorrhage in the patients and the stan-dardized anticoagulant therapy conditions were evaluated according to the 2010 update of the ESC (Euro-pean Society of Cardiology) guidelines for the management of atrial fibrillation. Results: The scores of CHA2DS2-VASc and HAS-BLED scheme were (2.73±2.10) points and (1.57±1.13) points,respectively. A-mong the 200 patients, 183 patients (91.5%) received antithrombosis therapy and 74 patients (37%) were on warfarin anticoagulant therapy. In the thromboembolic high risk group of 125 patients, only 50 patients (40%) received anticoagulant therapy with warfarin. The time of warfarin anticoagulant therapy were (5.78± 4.73) days and the total dose of warfarin were (19.46±18.19) mg. Among the 55 patients (74.32%) received monitoring the international normalized ratio (INR), the INR targeted rate was 30.9%. Conclusion: The current state of anticoagulant therapy with warfarin in the patients with atrial fibrillation is not optimistic and we must take measures effectively to improve the standard of anticoagulant therapy with warfarin in the patients with atrial fibrillation.
展开▼
